Skip NavigationSkip to Content
Return Return to Search Results

Prospective comparison of PI-RADS version 2 and qualitative in-house categorization system in detection of prostate cancer

  1. Author:
    Gaur, Sonia
    Harmon, Stephanie
    Mehralivand, Sherif
    Bednarova, Sandra
    Calio, Brian P
    Sugano, Dordaneh
    Sidana, Abhinav
    Merino, Maria J
    Pinto, Peter A
    Wood, Bradford J
    Shih, Joanna H
    Choyke, Peter L
    Turkbey, Baris

  2. Author Address

    Molecular Imaging Program, National Cancer Institute, NIH, Bethesda, Maryland, USA., Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, 21702., Urologic Oncology Branch, National Cancer Institute, NIH, Bethesda, Maryland, USA., Department of Pathology, National Cancer Institute, NIH, Bethesda, Maryland, USA., Center for Interventional Oncology, Clinical Center, NIH, Bethesda, Maryland, USA., Biometric Research Branch, National Cancer Institute, NIH, Bethesda, Maryland, USA.,
    1. Year: 2018
    2. Date: Nov
    3. Epub Date: 2018 03 31
  2. Journal: Journal of magnetic resonance imaging : JMRI
    1. 48
    2. 5
    3. Pages: 1326-1335
  4. Type of Article: Article
  5. ISSN: 1053-1807
  1. Abstract:

    BACKGROUND: Prostate Imaging-Reporting and Data System v. 2 (PI-RADSv2) provides standardized nomenclature for interpretation of prostate multiparametric MRI (mpMRI). Inclusion of additional features for categorization may provide benefit to stratification of disease. PURPOSE: To prospectively compare PI-RADSv2 to a qualitative in-house system for detecting prostate cancer on mpMRI. STUDY TYPE: Prospective. POPULATION: In all, 338 patients who underwent mpMRI May 2015-May 2016, with subsequent MRI/transrectal ultrasound fusion-guided biopsy. FIELD STRENGTH: 3T mpMRI (T2 W, diffusion-weighted [DW], apparent diffusion coefficient [ADC] map, b-2000 DWI acquisition, and dynamic contrast-enhanced [DCE] MRI). ASSESSMENT: One genitourinary radiologist prospectively read mpMRIs using both in-house and PI-RADSv2 5-category systems. STATISTICAL TEST: In lesion-based analysis, overall and clinically significant (CS) tumor detection rates (TDR) were calculated for all PI-RADSv2 and in-house categories. The ability of each scoring system to detect cancer was assessed by area under receiver operator characteristic curve (AUC). Within each PI-RADSv2 category, lesions were further stratified by their in-house categories to determine if TDRs can be increased by combining features of both systems. RESULTS: In 338 patients (median prostate-specific antigen [PSA] 6.5 [0.6-113.6] ng/mL; age 64 [44-84] years), 733 lesions were identified (47% tumor-positive). Predictive abilities of both systems were comparable for all (AUC 76-78%) and CS cancers (AUCs 79%). The in-house system had higher overall and CS TDRs than PI-RADSv2 for categories 3 and 4 (P?

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1002/jmri.26025
  3. PMID: 29603833
  4. PMCID: PMC6167212
  5. View record in Web of Science®
  6. WOS: 000448081300018

Library Notes

  1. Fiscal Year: FY2017-2018
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel